Outlook Therapeutics, Inc.
OTLK
$0.70
-$0.02-2.40%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/6/2026
-
SeekingAlpha
6/6/2026
-
Seeking Alpha - Healthcare
6/2/2026
-
Holdings Channel
6/1/2026
-
TipRanks Financial Blog
6/1/2026
-
Globe Newswire
5/29/2026
-
TipRanks Financial Blog
5/28/2026
-
TipRanks Financial Blog
5/28/2026
-
Seeking Alpha - Healthcare
5/28/2026
-
Globe Newswire
OTLK Stock Rocket Nearly 140%: FDA's Lytenava Approval Pushes Stock On Track For Best Week On Record
5/28/2026
-
Stocktwits News Feed
5/27/2026
-
Stocktwits News Feed
5/26/2026
-
Nasdaq News: Markets
5/26/2026
-
RTT News - Momentum Stocks
5/26/2026
-
Stocktwits News Feed
5/26/2026
-
Globe Newswire
5/17/2026
-
The Cerbat Gem
5/15/2026
-
Globe Newswire
5/13/2026
-
TipRanks Financial Blog
5/12/2026
-
The Cerbat Gem
4/23/2026
-
TipRanks Financial Blog
4/23/2026
-
Globe Newswire
4/22/2026
-
TipRanks Financial Blog
4/22/2026
-
Seeking Alpha - Healthcare
4/22/2026
-
Globe Newswire
4/21/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, May 15, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Aug 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
609 619 3990
Address
111 S. Wood Avenue
Iselin, NJ 08830
Iselin, NJ 08830
Country
Year Founded
Business Description
Sector
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product...
more